Adjuvant palbociclib in HR+/HER2-early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

被引：1
|
作者：
Gnant, Michael
Dueck, Amylou C.
Frantal, Sophie
Martin, Miguel
Burstein, Hal
Greil, Richard
Fox, Peter
Wolff, Antonio C.
Chan, Arlene
Winer, Eric
Singer, Christian
Miller, Kathy
Colleoni, Marco
Naughton, Michelle
Rubovszky, Gabor
Bliss, Judith
Mayer, Ingrid A.
Steger, Guenther G.
Nowecki, Zbigniew
Hahn, Olwen
Wolmark, Norman
Rugo, Hope
Pfeiler, Georg
Fohler, Hannes
Metzger, Otto
Schurmans, Celine
Theall, Kathy P.
Lu, Dongrui R.
Tenner, Kathleen
Fesl, Christian
DeMichele, Angela
Mayer, Erica L.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS1-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS1-07
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [42] Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
    Shinn, Eileen
    Zahrieh, David
    Demichele, Angela
    Zdenkowski, Nick
    Lemieux, Julie
    Mao, Jun
    Bjelic-Radisic, Vesna
    Naughton, Michelle J.
    Pfeiler, Georg
    Gelmon, Karen
    Balko, Justin M.
    Egle, Daniel
    Zoppoli, Gabriele
    Traina, Tiffany
    Jimenez, Miguel Martin
    Novoa, Silvia Antolin
    Haddad, Tufia
    Chan, Arlene
    Ring, Alistair
    Wolff, Antonio
    Symmans, William Fraser
    Ponce Lorenzo, Jose
    Sabanathan, Dhanusha
    Burstein, Hal J.
    Nowecki, Zbigniew Ireneusz
    Pristauz-Telsnigg, Gunda
    Brufsky, Adam
    Bellet-Ezquerra, Meritxell
    Foukakis, Theodoros
    Novik, Yelena
    Rubovszky, Gabor
    Singer, Christian F.
    Muehlbacher, Karoline
    Filho, Otto Metzger
    Goulioti, Theodora
    Law, Ernest
    Partridge, Ann H.
    Carey, Lisa A.
    Zoroufy, Alex
    Hlauschek, Dominik
    Fesl, Christian
    Mayer, Erica L.
    Gnant, Michael
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 385 - 397
  • [43] Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 4 - 5
  • [44] Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2-early breast cancer (eBC)
    Penault-Llorca, Frederique
    Dalenc, Florence
    Chabaud, Sylvie
    Cottu, Paul
    Allouache, Djelila
    Cameron, David
    Jacquin, Jean-Philippe
    Grenier, Julien
    Bouvet, Laurence Venat
    Jegannathen, Apurna
    Campone, Mario
    Del Piano, Francesco
    Debled, Marc
    Hardy-Bessard, Anne-Claire
    Giacchetti, Sylvie
    Barthelemy, Philippe
    Kaluzinski, Laure
    Mailliez, Audrey
    Mouret-Reynier, Marie-Ange
    Legouffe, Eric
    Cayre, Anne
    Martinez, Mathilde
    Delbaldo, Catherine
    Mollon-Grange, Delphine
    Macaskill, E. Jane
    Sephton, Matthew
    Stefani, Laetitia
    Belgadi, Blaha
    Winter, Matthew
    Orfeuvre, Hubert
    Lacroix-Triki, Magali
    Bonnefoi, Herve
    Bliss, Judith
    Canon, Jean-Luc
    Lemonnier, Jerome
    Andre, Fabrice
    Bachelot, Thomas
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
    Dieci, Maria Vittoria
    Bisagni, Giancarlo
    Brandes, Alba Ariela
    Frassoldati, Antonio
    Vicini, Roberto
    Balduzzi, Sara
    D'Amico, Roberto
    Conte, Pier Franco
    Guarneri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2-early breast cancer (eBC)
    Downer, Mary K.
    Craggs, Christopher
    Dhillon, Preet
    Luhn, Patricia
    Flores-Avile, Carlos
    Tan, Amie
    Patre, Monika
    Schimmoller, Frauke
    Crnjevic, Tanja Badovinac
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2-early breast cancer
    Janni, Wolfgang
    Untch, Michael
    Harbeck, Nadia
    Gligorov, Joseph
    Jacot, William
    Chia, Stephen
    Boileau, Jean-Francois
    Gupta, Subhajit
    Mishra, Namita
    Akdere, Murat
    Danyliv, Andriy
    Curigliano, Giuseppe
    BREAST, 2025, 81
  • [48] Use of the gene expression test Prosigna® in premenopausal patients with HR+, HER2-early breast cancer: Correlation of the results with the proliferation marker Ki-67
    Ziegler, Cordula
    Sotlar, Karl
    Hofmann, Daniel Maria
    Kolben, Thomas
    Harbeck, Nadia
    Wuerstlein, Rachel
    BREAST CARE, 2024, 19 (01) : 34 - 42
  • [49] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [50] Omission of Chemotherapy in HR+/HER2-Early Invasive Breast Cancer Based on Combined 6-IHC Score?
    Lin, Jiaman
    Guo, Zihe
    Wang, Shuo
    Zheng, Xinyu
    CLINICAL BREAST CANCER, 2021, 21 (05) : E565 - E574
12345